149 related articles for article (PubMed ID: 15139763)
1. Discovery of the first non-peptide full agonists for the human bradykinin B(2) receptor incorporating 4-(2-picolyloxy)quinoline and 1-(2-picolyl)benzimidazole frameworks.
Sawada Y; Kayakiri H; Abe Y; Mizutani T; Inamura N; Asano M; Hatori C; Aramori I; Oku T; Tanaka H
J Med Chem; 2004 May; 47(11):2853-63. PubMed ID: 15139763
[TBL] [Abstract][Full Text] [Related]
2. A new class of nonpeptide bradykinin B(2) receptor ligand, incorporating a 4-aminoquinoline framework. Identification of a key pharmacophore to determine species difference and agonist/antagonist profile.
Sawada Y; Kayakiri H; Abe Y; Mizutani T; Inamura N; Asano M; Aramori I; Hatori C; Oku T; Tanaka H
J Med Chem; 2004 May; 47(10):2667-77. PubMed ID: 15115408
[TBL] [Abstract][Full Text] [Related]
3. A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 4. Discovery of novel frameworks mimicking the active conformation.
Abe Y; Kayakiri H; Satoh S; Inoue T; Sawada Y; Inamura N; Asano M; Aramori I; Hatori C; Sawai H; Oku T; Tanaka H
J Med Chem; 1998 Nov; 41(23):4587-98. PubMed ID: 9804698
[TBL] [Abstract][Full Text] [Related]
4. A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 3. Discovering bioisosteres of the imidazo[1,2-a] pyridine moiety.
Abe Y; Kayakiri H; Satoh S; Inoue T; Sawada Y; Inamura N; Asano M; Aramori I; Hatori C; Sawai H; Oku T; Tanaka H
J Med Chem; 1998 Oct; 41(21):4062-79. PubMed ID: 9767643
[TBL] [Abstract][Full Text] [Related]
5. A new series of highly potent non-peptide bradykinin B2 receptor antagonists incorporating the 4-heteroarylquinoline framework. Improvement of aqueous solubility and new insights into species difference.
Sawada Y; Kayakiri H; Abe Y; Imai K; Mizutani T; Inamura N; Asano M; Aramori I; Hatori C; Katayama A; Oku T; Tanaka H
J Med Chem; 2004 Mar; 47(7):1617-30. PubMed ID: 15027853
[TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of novel sulfonamide-containing bradykinin hB2 receptor antagonists. 1. Synthesis and SAR of alpha,alpha-dimethylglycine sulfonamides.
Fattori D; Rossi C; Fincham CI; Berettoni M; Calvani F; Catrambone F; Felicetti P; Gensini M; Terracciano R; Altamura M; Bressan A; Giuliani S; Maggi CA; Meini S; Valenti C; Quartara L
J Med Chem; 2006 Jun; 49(12):3602-13. PubMed ID: 16759102
[TBL] [Abstract][Full Text] [Related]
7. MEN16132, a novel potent and selective nonpeptide antagonist for the human bradykinin B2 receptor. In vitro pharmacology and molecular characterization.
Cucchi P; Meini S; Bressan A; Catalani C; Bellucci F; Santicioli P; Lecci A; Faiella A; Rotondaro L; Giuliani S; Giolitti A; Quartara L; Maggi CA
Eur J Pharmacol; 2005 Dec; 528(1-3):7-16. PubMed ID: 16324696
[TBL] [Abstract][Full Text] [Related]
8. A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 2. Overcoming the species difference between guinea pig and man.
Abe Y; Kayakiri H; Satoh S; Inoue T; Sawada Y; Inamura N; Asano M; Hatori C; Sawai H; Oku T; Tanaka H
J Med Chem; 1998 Oct; 41(21):4053-61. PubMed ID: 9767642
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological characterization of a nonpeptide bradykinin B2 receptor antagonist, FR165649, and agonist, FR190997.
Asano M; Hatori C; Sawai H; Johki S; Inamura N; Kayakiri H; Satoh S; Abe Y; Inoue T; Sawada Y; Mizutani T; Oku T; Nakahara K
Br J Pharmacol; 1998 Jun; 124(3):441-6. PubMed ID: 9647466
[TBL] [Abstract][Full Text] [Related]
10. Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 2. Identification of (S)-N-(1-phenylpropyl)-3-hydroxy-2-phenylquinoline-4-carboxamide (SB 223412).
Giardina GA; Raveglia LF; Grugni M; Sarau HM; Farina C; Medhurst AD; Graziani D; Schmidt DB; Rigolio R; Luttmann M; Cavagnera S; Foley JJ; Vecchietti V; Hay DW
J Med Chem; 1999 Mar; 42(6):1053-65. PubMed ID: 10090788
[TBL] [Abstract][Full Text] [Related]
11. Fish somatostatin sst3 receptor: comparison of radioligand and GTPgammaS binding, adenylate cyclase and phospholipase C activities reveals different agonist-dependent pharmacological signatures.
Siehler S; Nunn C; Zupanc GK; Hoyer D
Auton Autacoid Pharmacol; 2005 Jan; 25(1):1-16. PubMed ID: 15659149
[TBL] [Abstract][Full Text] [Related]
12. The N-terminal of icatibant and bradykinin interact with the same Asp residues in the human B2 receptor.
Bellucci F; Meini S; Cucchi P; Catalani C; Giuliani S; Zappitelli S; Rotondaro L; Quartara L; Giolitti A; Maggi CA
Eur J Pharmacol; 2004 May; 491(2-3):121-5. PubMed ID: 15140628
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological and functional characterization of the guinea-pig B2 bradykinin receptor stably expressed in CHO-K1 cell line.
Robert C; Pruneau D; Paquet JL
Br J Pharmacol; 2002 Jan; 135(2):462-8. PubMed ID: 11815382
[TBL] [Abstract][Full Text] [Related]
14. A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 1. Construction of the basic framework.
Abe Y; Kayakiri H; Satoh S; Inoue T; Sawada Y; Imai K; Inamura N; Asano M; Hatori C; Katayama A; Oku T; Tanaka H
J Med Chem; 1998 Feb; 41(4):564-78. PubMed ID: 9484506
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of novel sulfonamide-containing bradykinin hB2 receptor antagonists. 2. Synthesis and structure-activity relationships of alpha,alpha-cycloalkylglycine sulfonamides.
Fattori D; Rossi C; Fincham CI; Caciagli V; Catrambone F; D'Andrea P; Felicetti P; Gensini M; Marastoni E; Nannicini R; Paris M; Terracciano R; Bressan A; Giuliani S; Maggi CA; Meini S; Valenti C; Quartara L
J Med Chem; 2007 Feb; 50(3):550-65. PubMed ID: 17266207
[TBL] [Abstract][Full Text] [Related]
16. Novel small molecule bradykinin B2 receptor antagonists.
Gibson C; Schnatbaum K; Pfeifer JR; Locardi E; Paschke M; Reimer U; Richter U; Scharn D; Faussner A; Tradler T
J Med Chem; 2009 Jul; 52(14):4370-9. PubMed ID: 19552431
[TBL] [Abstract][Full Text] [Related]
17. Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4.
Cheng LL; Stoev S; Manning M; Derick S; Pena A; Mimoun MB; Guillon G
J Med Chem; 2004 Apr; 47(9):2375-88. PubMed ID: 15084136
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological characterization and radioligand binding properties of a high-affinity, nonpeptide, bradykinin B1 receptor antagonist.
Ransom RW; Harrell CM; Reiss DR; Murphy KL; Chang RS; Hess JF; Miller PJ; O'Malley SS; Hey PJ; Kunapuli P; Su DS; Markowitz MK; Wallace MA; Raab CE; Jones AN; Dean DC; Pettibone DJ; Freidinger RM; Bock MG
Eur J Pharmacol; 2004 Sep; 499(1-2):77-84. PubMed ID: 15363953
[TBL] [Abstract][Full Text] [Related]
19. Differences between peptide and nonpeptide B(2) bradykinin receptor antagonists in blocking bronchoconstriction and hypotension induced by bradykinin in anesthetized Guinea pigs.
Tramontana M; Lecci A; Meini S; Montserrat X; Pascual J; Giuliani S; Quartara L; Maggi CA
J Pharmacol Exp Ther; 2001 Mar; 296(3):1051-7. PubMed ID: 11181940
[TBL] [Abstract][Full Text] [Related]
20. Dual antagonists of the bradykinin B1 and B2 receptors based on a postulated common pharmacophore from existing non-peptide antagonists.
Morissette G; Bouthillier J; Marceau F
Biol Chem; 2006 Feb; 387(2):189-94. PubMed ID: 16497151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
